Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Alteryx Therapeutics Ltd in metadata) covers the first quarter ended September 30, 2014. The report was filed on October 30, 2014, and includes an Appendix 4C Quarterly Report for entities admitted on the basis of commitments.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Revenue (Receipts from customers) | 0 |
| Net Operating Cash Flows | (4,368) |
| Net Investing Cash Flows | (13) |
| Net Financing Cash Flows | (8) |
| Net Decrease in Cash | (4,389) |
| Cash at Beginning of Quarter | 34,167 |
| Cash at End of Quarter | 31,835 |
| Debt/Borrowings | 0 (No borrowings or repayments reported) |
Operating Expenses: The company reported significant cash outflows for research and development ($3,159k), staff costs ($670k), and other working capital ($704k). Interest received was $86k, and grants/donations received were $113k.
Material Changes and Activities
- Cash Burn: The company consumed approximately $4.4 million in cash during the quarter, primarily driven by R&D expenditures.
- Non-Cash Transactions: 110,000 shares were issued to employees and consultants under the Employee Incentive Scheme and Consulting Agreements.
- Related Party Payments: $179k was paid to directors and associates for salaries, fees, and consulting at normal commercial rates.
- Investing Activities: Minimal investing activity occurred, with only $13k spent on physical non-current assets.
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, revenue forecasts, or management commentary regarding future market conditions. The report focuses strictly on historical cash flow data and compliance with ASX listing rules for entities admitted on the basis of commitments. No specific risks or contingencies were detailed in the provided text beyond the inherent cash burn associated with a pre-revenue biotechnology entity.
Investor Verification Checklist
- Verify the company's runway by comparing the $31.8 million cash balance against the current quarterly burn rate of ~$4.4 million.
- Confirm the status of the 110,000 shares issued to employees and consultants and their impact on dilution.
- Review the specific milestones achieved with the $3.159 million spent on research and development.
- Check for any subsequent capital raising activities given the lack of financing proceeds in this quarter.